U.S. Markets open in 19 hrs, 11 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 8,451.19 | -128.00 | -1.49% |
| NASDAQ | 1,649.51 | 4.39 | 0.27% |
| S&P 500 | 899.22 | -10.70 | -1.18% |
| Day Low 12:13 PM EDT | 2.75 | |
|---|---|---|
| Day High 03:55 PM EDT | 2.99 |
|
| Range | 0.24 | |
| Volume | 9,847 | |
| 30-Day Avg. Vol. | 146,000 |
|
| Difference | -93.26% | |
| Market Cap. | 89 M | |
| Change | 6.54 M | |
| Shares Out. | 29.76 M | |
| Percent Traded | 0.03% | |
| Revenue (LFY) | 0 | |
| Earnings (TTM) | -25.16 M | |
| Next Earnings | 10/20/2008 |
|
| EPS (TTM) | -0.96 |
| 52-Wk Low 4/9/08 | 2.37 | |
|---|---|---|
| 52-Wk High 10/11/07 | 5.50 |
|
| Range | 3.13 | |
| Prev. Close 10/9/08 | 2.77 | |
| Today's Open | 2.78 | |
| Change | 0.36% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 1.1799 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | — |
Avigen has decided to go back to pharmaceutical basics. While the company had focused its development efforts on gene therapies for Parkinson's disease and hemophilia, it has shifted its focus to small-molecule ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.255 3/31/08 | -0.25 3/31/08 |
0.005
Beat
|
| Last Quarter | -0.258 6/30/08 | -0.25 6/30/08 |
0.008
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | — | -1.59 M |
| Operating Income | -8.16 M | -29.31 M |
| Net Income | -7.34 M | -25.16 M |
